What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?

Ramon Andrade De Mello1, Luis Castelo-Branco1, Pedro Castelo-Branco1

  • 1From the Department of Biomedical Sciences and Medicine, Division of Oncology, University of Algarve, Faro, Portugal; Algarve Biomedical Center, Campus Gambelas, Faro, Portugal; Faculty of Medicine, University of Porto, Porto, Portugal; Research Centre, Division of Medical Oncology, Hospital São Mateus, NOHC Clinic, Fortaleza, CE, Brazil; Algarve Hospital and University Center, Department of Oncology, Faro, Portugal; Portuguese Public Health School, Nova University, Lisbon, Portugal; Centre for Biomedical Research, University of Algarve, Faro, Portugal; Department of Biomedicine, Faculty of Medicine, University of Porto, Porto, Portugal; Faculty of Nutrition and Food Sciences, University of Porto, Porto, Portugal; Academic Medical Center Amsterdam, Center for Experimental Molecular Medicine, Amsterdam, The Netherlands; and the Division of Medical Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.

Insights

Novel targeted therapies are emerging for esophageal and gastric cancers. Research highlights PIK3CA mutations and PARP-1 expression as potential targets, alongside immunotherapy for specific patient groups.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Esophageal and gastric cancers are aggressive malignancies with evolving treatment landscapes.
  • Several molecular pathways, including VEGF, EGFR, FGFR, PIK3CA, and PARP-1, are implicated in these cancers.
  • Emerging research suggests potential for novel targeted drugs and immunotherapies.

Purpose of the Study:

  • To review current trends and future potential of novel therapies for esophageal and gastric cancers.
  • To explore the significance of specific molecular pathways (PIK3CA, PARP-1) and biomarkers (PD-L1, MSI, dMMR) in gastric cancer treatment.
  • To discuss the implications of these findings for systemic treatment strategies.

Main Methods:

  • Review of The Cancer Genome Atlas (TCGA) report findings.
  • Analysis of molecular pathway alterations in esophageal and gastric cancers.
  • Discussion of biomarker expression (PD-L1, MSI, dMMR) and their therapeutic relevance.

Main Results:

  • PIK3CA mutations are prevalent in Epstein-Barr virus-positive and microsatellite instability-high gastric tumors.
  • Elevated PARP-1 expression in gastric cancer correlates with advanced disease and poorer prognosis.
  • PD-L1 expression, high microsatellite instability, and mismatch repair deficiency indicate potential for immunotherapy.

Conclusions:

  • PIK3CA pathway warrants reevaluation as a therapeutic target for gastric cancer.
  • PARP-1 expression levels may serve as a prognostic indicator in gastric cancer.
  • Immunotherapy holds promise for a subset of gastric cancer patients with specific biomarkers.

Related Concept Videos

Expected Value01:15

Expected Value

The expected value is known as the "long-term" average or mean. This means that over the long term of experimenting over and over, you would expect this average. The expected average is represented by the symbol μ. It is calculated as follows:
7.8K
Determination of Expected Frequency01:08

Determination of Expected Frequency

Suppose one wants to test independence between the two variables of a contingency table. The values in the table constitute the observed frequencies of the dataset. But how does one determine the expected frequency of the dataset? One of the important assumptions is that the two variables are independent, which means the variables do not influence each other. For independent variables, the statistical probability of any event involving both variables is calculated by multiplying the individual...
2.6K
Esophageal Varices-I: Introduction01:24

Esophageal Varices-I: Introduction

Esophageal varices are dilated, tortuous veins which are found mainly in the submucosa of the lower esophagus but which may also appear higher up or extend into the stomach. They develop due to increased pressure in the portal venous system, often as a result of liver cirrhosis. This condition scars and damages the liver, impeding normal blood flow through the portal vein. To compensate, blood seeks alternative pathways, forming fragile new vessels (varices) in the esophagus and stomach. These...
1.5K
Gastric Motility01:16

Gastric Motility

Gastric motility is the coordinated contraction and relaxation of stomach muscles that convert ingested food into chyme, a semi-liquid substance ready for further digestion in the intestines. The process begins with the vagus nerve inducing the relaxation of the smooth muscles in the fundus and body of the stomach, allowing these regions to expand and accommodate up to approximately 1.5 liters of food and liquid.
Peristaltic Waves and Chyme Formation
Upon food entry, the stomach initiates...
3.2K
Gastric Emptying01:16

Gastric Emptying

Gastric emptying occurs when the stomach gradually releases chyme into the duodenum. When the stomach is distended, it triggers the release of gastrin, a hormone that promotes gastric acid secretion to aid in digestion. Additionally, stomach distension contributes to peristaltic waves that propel gastric contents toward the pyloric region. The gastroenteric reflex, on the other hand, primarily stimulates peristalsis in the intestines, facilitating the movement of contents further along the...
3.8K
Esophageal Perforation-I: Introduction01:22

Esophageal Perforation-I: Introduction

Esophageal perforation is a severe medical condition characterized by a breach in the integrity of the esophageal wall. This breach can occur due to various factors such as trauma, medical procedures, or underlying diseases. When the esophageal wall is compromised, it allows food, fluids, and digestive juices into the chest cavity or adjacent structures, leading to potential complications and health risks.
The location of esophageal perforation can vary, occurring anywhere along the esophagus....
612